{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:52:38Z","timestamp":1760921558123,"version":"3.37.3"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["15ek0410004h0003"],"award-info":[{"award-number":["15ek0410004h0003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1387-9","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T11:38:46Z","timestamp":1502451526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study"],"prefix":"10.1186","volume":"19","author":[{"given":"Jin","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0180-699X","authenticated-orcid":false,"given":"Yoshinobu","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Horiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuteru","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,11]]},"reference":[{"issue":"18","key":"1387_CR1","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","volume":"322","author":"ED Harris Jr","year":"1990","unstructured":"Harris Jr ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990;322(18):1277\u201389.","journal-title":"N Engl J Med"},{"issue":"12","key":"1387_CR2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681\u201390.","journal-title":"Arthritis Rheum"},{"issue":"9410","key":"1387_CR3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675\u201381.","journal-title":"Lancet"},{"issue":"1","key":"1387_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26\u201337.","journal-title":"Arthritis Rheum"},{"issue":"9685","key":"1387_CR5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210\u201321.","journal-title":"Lancet"},{"issue":"12","key":"1387_CR6","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","volume":"46","author":"EH Choy","year":"2002","unstructured":"Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46(12):3143\u201350.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1387_CR7","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(6):1761\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1387_CR8","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","volume":"36","author":"M Mertens","year":"2009","unstructured":"Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36(6):1118\u201325.","journal-title":"J Rheumatol"},{"issue":"11","key":"1387_CR9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114\u201323.","journal-title":"N Engl J Med"},{"issue":"5","key":"1387_CR10","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390\u2013400.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1387_CR11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1387_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/acr.22783","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges Jr SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1\u201325.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"1387_CR13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","volume":"62","author":"R Vollenhoven van","year":"2003","unstructured":"van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis. 2003;62(12):1195\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1387_CR14","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"1387_CR15","doi-asserted-by":"crossref","first-page":"v22","DOI":"10.1093\/rheumatology\/kes115","volume":"51","author":"P Emery","year":"2012","unstructured":"Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford). 2012;51 Suppl 5:v22\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1387_CR16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/annrheumdis-2011-200882","volume":"71","author":"SM Pan Du","year":"2012","unstructured":"Du Pan SM, Scherer A, Gabay C, Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71(6):997\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1387_CR17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3143\/geriatrics.31.548","volume":"31","author":"Y Ohhara","year":"1994","unstructured":"Ohhara Y, Sakurada K, Miyazaki T, Sugimura I. Longitudinal assessment of hematological parameters in the elderly. Nihon Ronen Igakkai Zasshi. 1994;31(7):548\u201353.","journal-title":"Nihon Ronen Igakkai Zasshi"},{"issue":"5","key":"1387_CR18","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/ard.2010.139725","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70(5):755\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1387_CR19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum. 2010;62(1):22\u201332.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1387_CR20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","volume":"73","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewe R. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529\u201335.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1387_CR21","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/acr.22765","volume":"68","author":"J Wang","year":"2016","unstructured":"Wang J, Devenport J, Low JM, Yu D, Hitraya E. Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res. 2016;68(6):882\u20135.","journal-title":"Arthritis Care Res"},{"issue":"7347","key":"1387_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10098","volume":"473","author":"B Schwanhausser","year":"2011","unstructured":"Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature. 2011;473(7347):337\u201342.","journal-title":"Nature"},{"issue":"11","key":"1387_CR23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1056\/NEJM199809103391107","volume":"339","author":"K Kaushansky","year":"1998","unstructured":"Kaushansky K. Thrombopoietin. N Engl J Med. 1998;339(11):746\u201354.","journal-title":"N Engl J Med"},{"issue":"9","key":"1387_CR24","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V98.9.2720","volume":"98","author":"A Kaser","year":"2001","unstructured":"Kaser A, Brandacher G, Steurer W, Kaser S, Offner FA, Zoller H, Theurl I, Widder W, Molnar C, Ludwiczek O, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720\u20135.","journal-title":"Blood"},{"issue":"6481","key":"1387_CR25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","volume":"369","author":"FJ Sauvage de","year":"1994","unstructured":"de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994;369(6481):533\u20138.","journal-title":"Nature"},{"issue":"7","key":"1387_CR26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","volume":"77","author":"TD Bartley","year":"1994","unstructured":"Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, Chang MS, Samal B, Nichol JL, Swift S, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77(7):1117\u201324.","journal-title":"Cell"},{"issue":"11","key":"1387_CR27","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V85.11.3066.bloodjournal85113066","volume":"85","author":"MS Gordon","year":"1995","unstructured":"Gordon MS, Nemunaitis J, Hoffman R, Paquette RL, Rosenfeld C, Manfreda S, Isaacs R, Nimer SD. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood. 1995;85(11):3066\u201376.","journal-title":"Blood"},{"issue":"5","key":"1387_CR28","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood.V84.5.1434.1434","volume":"84","author":"MM Gameren van","year":"1994","unstructured":"van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, de Vries EG. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood. 1994;84(5):1434\u201341.","journal-title":"Blood"},{"issue":"11","key":"1387_CR29","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","volume":"276","author":"CH Park","year":"2001","unstructured":"Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276(11):7806\u201310.","journal-title":"J Biol Chem"},{"issue":"3","key":"1387_CR30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","volume":"102","author":"T Ganz","year":"2003","unstructured":"Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102(3):783\u20138.","journal-title":"Blood"},{"issue":"1","key":"1387_CR31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cell.2010.06.028","volume":"142","author":"MW Hentze","year":"2010","unstructured":"Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of mammalian iron metabolism. Cell. 2010;142(1):24\u201338.","journal-title":"Cell"},{"issue":"9","key":"1387_CR32","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","volume":"108","author":"DM Wrighting","year":"2006","unstructured":"Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204\u20139.","journal-title":"Blood"},{"issue":"7","key":"1387_CR33","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","volume":"101","author":"E Nemeth","year":"2003","unstructured":"Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461\u20133.","journal-title":"Blood"},{"issue":"1","key":"1387_CR34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.510310123","volume":"31","author":"K Kovalovich","year":"2000","unstructured":"Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology. 2000;31(1):149\u201359.","journal-title":"Hepatology"},{"issue":"28","key":"1387_CR35","doi-asserted-by":"crossref","first-page":"26605","DOI":"10.1074\/jbc.M100740200","volume":"276","author":"K Kovalovich","year":"2001","unstructured":"Kovalovich K, Li W, DeAngelis R, Greenbaum LE, Ciliberto G, Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J Biol Chem. 2001;276(28):26605\u201313.","journal-title":"J Biol Chem"},{"issue":"4","key":"1387_CR36","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.bbrc.2003.08.085","volume":"309","author":"LP James","year":"2003","unstructured":"James LP, Lamps LW, McCullough S, Hinson JA. Interleukin 6 and hepatocyte regeneration in acetaminophen toxicity in the mouse. Biochem Biophys Res Commun. 2003;309(4):857\u201363.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5291","key":"1387_CR37","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.274.5291.1379","volume":"274","author":"DE Cressman","year":"1996","unstructured":"Cressman DE, Greenbaum LE, DeAngelis RA, Ciliberto G, Furth EE, Poli V, Taub R. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 1996;274(5291):1379\u201383.","journal-title":"Science"},{"issue":"3","key":"1387_CR38","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1053\/jhep.2003.50378","volume":"38","author":"A Blindenbacher","year":"2003","unstructured":"Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH. Interleukin 6 is important for survival after partial hepatectomy in mice. Hepatology. 2003;38(3):674\u201382.","journal-title":"Hepatology"},{"issue":"7","key":"1387_CR39","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1172\/JCI200317970","volume":"112","author":"S Haga","year":"2003","unstructured":"Haga S, Terui K, Zhang HQ, Enosawa S, Ogawa W, Inoue H, Okuyama T, Takeda K, Akira S, Ogino T, et al. Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms. J Clin Invest. 2003;112(7):989\u201398.","journal-title":"J Clin Invest"},{"issue":"4","key":"1387_CR40","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1172\/JCI23640","volume":"115","author":"C Klein","year":"2005","unstructured":"Klein C, Wustefeld T, Assmus U, Roskams T, Rose-John S, Muller M, Manns MP, Ernst M, Trautwein C. The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest. 2005;115(4):860\u20139.","journal-title":"J Clin Invest"},{"issue":"5","key":"1387_CR41","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.2353\/ajpath.2010.090469","volume":"176","author":"W Plum","year":"2010","unstructured":"Plum W, Tschaharganeh DF, Kroy DC, Corsten E, Erschfeld S, Dierssen U, Wasmuth H, Trautwein C, Streetz KL. Lack of glycoprotein 130\/signal transducer and activator of transcription 3-mediated signaling in hepatocytes enhances chronic liver injury and fibrosis progression in a model of sclerosing cholangitis. Am J Pathol. 2010;176(5):2236\u201346.","journal-title":"Am J Pathol"},{"issue":"7","key":"1387_CR42","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1172\/JCI19974","volume":"112","author":"R Taub","year":"2003","unstructured":"Taub R. Hepatoprotection via the IL-6\/Stat3 pathway. J Clin Invest. 2003;112(7):978\u201380.","journal-title":"J Clin Invest"},{"issue":"32","key":"1387_CR43","doi-asserted-by":"crossref","first-page":"28411","DOI":"10.1074\/jbc.M202807200","volume":"277","author":"W Li","year":"2002","unstructured":"Li W, Liang X, Kellendonk C, Poli V, Taub R. STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration. J Biol Chem. 2002;277(32):28411\u20137.","journal-title":"J Biol Chem"},{"issue":"5770","key":"1387_CR44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.1123842","volume":"312","author":"M Lesurtel","year":"2006","unstructured":"Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet C, Bader M, Clavien PA. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312(5770):104\u20137.","journal-title":"Science"},{"issue":"5","key":"1387_CR45","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1084\/jem.179.5.1529","volume":"179","author":"H Mizuhara","year":"1994","unstructured":"Mizuhara H, O\u2019Neill E, Seki N, Ogawa T, Kusunoki C, Otsuka K, Satoh S, Niwa M, Senoh H, Fujiwara H. T cell activation-associated hepatic injury: mediation by tumor necrosis factors and protection by interleukin 6. J Exp Med. 1994;179(5):1529\u201337.","journal-title":"J Exp Med"},{"issue":"22","key":"1387_CR46","doi-asserted-by":"crossref","first-page":"15258","DOI":"10.1074\/jbc.M512953200","volume":"281","author":"Y Wang","year":"2006","unstructured":"Wang Y, Singh R, Lefkowitch JH, Rigoli RM, Czaja MJ. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem. 2006;281(22):15258\u201367.","journal-title":"J Biol Chem"},{"issue":"2","key":"1387_CR47","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/MCB.01166-06","volume":"27","author":"X Chen","year":"2007","unstructured":"Chen X, Ding WX, Ni HM, Gao W, Shi YH, Gambotto AA, Fan J, Beg AA, Yin XM. Bid-independent mitochondrial activation in tumor necrosis factor alpha-induced apoptosis and liver injury. Mol Cell Biol. 2007;27(2):541\u201353.","journal-title":"Mol Cell Biol"},{"issue":"6","key":"1387_CR48","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, Rohane P, van Hoogstraten H, Garg A, Fan C, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424\u201337.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1387_CR49","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1387_CR50","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/annrheumdis-2011-200704","volume":"71","author":"P Mease","year":"2012","unstructured":"Mease P, Strand V, Shalamberidze L, Dimic A, Raskina T, Xu LA, Liu Y, Smith J. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis. 2012;71(7):1183\u20139.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T22:26:22Z","timestamp":1602714382000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1387-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1387-9","relation":{},"ISSN":["1478-6362"],"issn-type":[{"type":"electronic","value":"1478-6362"}],"subject":[],"published":{"date-parts":[[2017,8,11]]},"article-number":"185"}}